Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...

A Northwestern Medicine study published in Nature Communications has revealed how HIV can protect infected cells by altering the sugars on their surface, hindering the host immune system and avoiding ...

In a groundbreaking discovery, researchers from Florida Atlantic University's Charles E. Schmidt College of Medicine have identified a never-before-seen mechanism that enables the human ...

In 2022, there were up to 1.2 million people with HIV (PWH) and 37,981 new cases of HIV in the United States alone. 1 While impressive advances have been made in HIV treatment and prevention, there ...